Royal Bank of Canada
FHTX icon

Royal Bank of Canada’s Foghorn Therapeutics FHTX Stock Holding History

Royal Bank of Canada’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
24
-980
-98% -$5.38K ﹤0.01% 7296
2025
Q4 		$6K Sell
1,004
-732
-42% -$3.32K ﹤0.01% 6633
2025
Q3 		$8K Buy
1,736
+672
+63% +$3.56K ﹤0.01% 6564
2025
Q2 		$4K Buy
1,064
+1,030
+3,029% +$4.3K ﹤0.01% 6681
2025
Q1 		$0 Sell
34
-2,555
-99% -$11.6K ﹤0.01% 6938
2024
Q4 		$12K Sell
2,589
-253
-9% -$1.84K ﹤0.01% 6288
2024
Q3 		$27K Sell
2,842
-6,534
-70% -$47.3K ﹤0.01% 5993
2024
Q2 		$54K Buy
9,376
+928
+11% +$5.53K ﹤0.01% 5608
2024
Q1 		$57K Buy
8,448
+1,947
+30% +$10.8K ﹤0.01% 5476
2023
Q4 		$42K Buy
6,501
+307
+5% +$1.32K ﹤0.01% 6067
2023
Q3 		$31K Sell
6,194
-1,272
-17% -$9.8K ﹤0.01% 6010
2023
Q2 		$53K Sell
7,466
-34
-0.5% -$238 ﹤0.01% 5752
2023
Q1 		$46K Buy
7,500
+1,101
+17% +$7.21K ﹤0.01% 5663
2022
Q4 		$40K Buy
6,399
+2,954
+86% +$22.3K ﹤0.01% 6009
2022
Q3 		$29K Buy
3,445
+132
+4% +$1.7K ﹤0.01% 5989
2022
Q2 		$46K Sell
3,313
-1,089
-25% -$14.1K ﹤0.01% 5747
2022
Q1 		$67K Sell
4,402
-2,716
-38% -$37.3K ﹤0.01% 5898
2021
Q4 		$162K Buy
7,118
+1,571
+28% +$22.6K ﹤0.01% 5539
2021
Q3 		$78K Buy
5,547
+2,959
+114% +$32.8K ﹤0.01% 5871
2021
Q2 		$27K Buy
2,588
+1,309
+102% +$14.3K ﹤0.01% 6395
2021
Q1 		$17K Buy
1,279
+907
+244% +$14.9K ﹤0.01% 6515
2020
Q4 		$8K Buy
+372
New +$7.13K ﹤0.01% 6475

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Royal Bank of Canada's FHTX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Foghorn Therapeutics (FHTX) stake by 98% in Q1 2026, selling an estimated $5.38K and leaving 24 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7296.

Royal Bank of Canada first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $162K in Q4 2021. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Royal Bank of Canada held 24 shares of Foghorn Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 980 Foghorn Therapeutics shares in Q1 2026, an estimated $5.38K.
  • Foghorn Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7296 holding.
  • Royal Bank of Canada first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's Foghorn Therapeutics position peaked at $162K in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.